Brilliant Violet 421™ anti-mouse CD274 (B7-H1, PD-L1) Antibody

Pricing & Availability
Clone
10F.9G2 (See other available formats)
Regulatory Status
RUO
Other Names
B7-H1, PD-L1
Isotype
Rat IgG2b, κ
10F.9G2_BV421_051311
C57BL/6 mouse splenocytes were stained with CD274 (clone 10F.9G2) Brilliant Violet 421™ (filled histogram), or rat IgG2b, κ Brilliant Violet 421™ isotype control (open histogram).
  • 10F.9G2_BV421_051311
    C57BL/6 mouse splenocytes were stained with CD274 (clone 10F.9G2) Brilliant Violet 421™ (filled histogram), or rat IgG2b, κ Brilliant Violet 421™ isotype control (open histogram).
Compare all formats See Brilliant Violet 421™ spectral data
Cat # Size Price Quantity Check Availability
124315 125 µL $204.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. It is expressed on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes. B7-H1 is one of the ligands of PD-1. The interaction of B7-H1 with PD-1 plays an important role in the inhibition of T cell responses. Other studies have shown that B7-H1 is able to costimulate T cell growth and cytokine production. CD274 is involved in costimulation essential for T cell proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-independent manner. Its interaction with PD-1 inhibits T cell proliferation and cytokine production.

Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence4, blocking6,7,8,9, and immunohistochemistry of acetone-fixed frozen sections4, 11. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 124303). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 124318) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Maier H, et al. 2007. J. Immunol. 178:2714.
  2. Meng Q, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:4444. PubMed
  3. Scarlett UK, et al. 2012. J Exp Med. 209:495. PubMed
  4. Grabie N, et al. 2007. Circulation 116:2062. (IF, IHC)
  5. Paterson AM, et al. 2011. J. Immunol. 187:1097.
  6. Channappanavar R, et al. 2012. PLoS One 7:e39757. (Block)
  7. Schreiber HA, et al. 2010. PLoS One 5:e11453. (Block) PubMed
  8. Muthumani K, et al. 2011. J. Immunol. 187:2932. (Block) PubMed
  9. Cripps JG, et al. 2010. Hepatology 52:1350. (Block) PubMed
  10. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  11. Riella LV, et al. 2011. Am. J. Transplant 11:832-40. (IHC)
  12. Lei GS, et al. 2015. Infect Immun. 83:572. PubMed
Product Citations
  1. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  2. Zhou L, et al. 2022. PLoS Negl Trop Dis. 16:e0010851. PubMed
  3. Tunali G, et al. 2023. J Clin Invest. :. PubMed
  4. Balakrishnan PB, et al. 2022. Nano Res. 15:2300. PubMed
  5. Yao RQ, et al. 2022. Theranostics. 12:4606. PubMed
  6. Wei H, et al. 2021. Malar J. 20:89. PubMed
  7. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  8. Best SA, et al. 2018. Cell Metab. 27:935. PubMed
  9. Hsu JM, et al. 2018. Nat Commun. 9:1908. PubMed
  10. Stewart JM, et al. 2020. ACS Biomater Sci Eng. 6:5941. PubMed
  11. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  12. Giesen D, et al. 2020. Clin Cancer Res. 26:3999. PubMed
  13. Puigdelloses M, et al. 2021. J Immunother Cancer. 9:. PubMed
  14. Walsh SM, et al. 2021. eLife. 10:00. PubMed
  15. Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed
  16. Yu D, et al. 2019. Cell Commun Signal. 0.828472222. PubMed
  17. Jiao S, et al. 2017. Clin Cancer Res. 23:3711. PubMed
  18. Zhao Y, et al. 2020. Immunity. 51(6):1059-1073.e9.. PubMed
  19. Vogel A, et al. 2022. Cell Rep. 38:110420. PubMed
  20. Ng KW, et al. 2019. eLife. 0.333333333333333. PubMed
  21. van der Velden V, et al. 2017. J Immunol Methods. 10.1016/j.jim.2017.03.011. PubMed
  22. Rosato PC, et al. 2019. Nat Commun. 10:567. PubMed
  23. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
  24. Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed
  25. Freed-Pastor WA, et al. 2021. Cancer Cell. 39:1342. PubMed
  26. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
  27. O'Reilly LA, et al. 2018. Immunity. 48:570. PubMed
  28. Lucas ED, et al. 2020. Cell Reports. 33(2):108258. PubMed
RRID
AB_10897097 (BioLegend Cat. No. 124315)

Antigen Details

Structure
40 kD type I transmembrane protein member of B7 family within the immunoglobulin receptor superfamily
Distribution

T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes

Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Endothelial cells, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.
2. Dong H, et al. 1999. Nat. Med. 5:1365.
3. Freeman G, et al. 2000. J. Exp. Med. 192:1027.

Gene ID
60533 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org
Go To Top Version: 2    Revision Date: 12/22/2014

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Login/Register
Forgot your password? Reset Password
Request an Account